AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update
- Continued execution across pipeline positions AIM to achieve multiple clinical and regulatory value-driving milestones throughout 2023- Lead clinical program, Phase 2 locally advance pancreatic cancer study, expected to enroll first patient this quarter - Phase 2...
AIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and Webcast
OCALA, Fla., May 09, 2023 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases - including...
AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB)
Company's SAB is comprised of well-established leaders with expertise across biomedical research, academia, and pharmaceutical industry OCALA, Fla., April 12, 2023 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), an immuno-pharma company focused...
Recent SEC Filings